View:
Download DOC
Download PDF
Download XLS
Download XBRL
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 16, 2024

AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
000-50761
11-3146460
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

14 Plaza Drive, Latham, New York                      
  12110
(Address of Principal Executive Offices)                
   (Zip Code)
     
(518) 795-1400
    
(Registrant’s telephone number, including area code)
    
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
 
Common Stock, par value $0.01 per share
          ANGO
NASDAQ Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 2.02 – Results of Operations and Financial Condition.

AngioDynamics, Inc. (“AngioDynamics”) is voluntarily providing pro forma condensed combined financial statements as of and for the fiscal quarters ended August 31, 2022, November 30, 2022 and February 28, 2023, August 31, 2023, November 30, 2023 and February 29, 2024, as described in Item 9.01 below, giving effect to the completion of the sale of AngioDynamics’ dialysis and BioSentry businesses to Merit Medical Systems, Inc. on June 8, 2023, as previously disclosed on AngioDynamics’ Current Report on Form 8-K filed with the Securities and Exchange Commission on June 14, 2023, the sale of AngioDynamics’ PICC and Midline product portfolios to Spectrum Vascular on February 24, 2024 and the discontinuation of the RadioFrequency ablation and Syntrax support catheter products as of February 29, 2024 (collectively, the “Businesses”).

The pro forma financial information included with this report in Item 9.01 (including Exhibit 99.1) has been presented for informational purposes only and is incorporated by reference into this Item 2.02.

The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Forward-Looking Statements

This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects”, “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2023. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Item 9.01 – Financial Statements and Exhibits.

(b)          Pro forma financial information.

Attached hereto as Exhibit 99.1 and incorporated by reference is the following unaudited pro forma financial information, in each case giving pro forma effect to the sale of the Businesses, for each of the three-month periods ended August 31, 2022, November 30, 2022 and February 28, 2023, August 31, 2023, November 30, 2023 and February 29, 2024:


 •
unaudited pro forma consolidated income statements;


•
net sales and gross profit by product category; and


•
notes to the unaudited pro forma consolidated financial statements.

(d)
Exhibits.

 
 Exhibit No.
Description
     
 
Unaudited Pro Forma Financial Information

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ANGIODYNAMICS, INC.
 
(Registrant)
     
Date:  July 16, 2024
By:
/s/ Stephen A. Trowbridge
  Name:
   Stephen A. Trowbridge
  Title:
   Executive Vice President and Chief Financial Officer


Exhibit 99.1
 
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share data)
 
   
Three Months Ended
    
Three Months Ended
  
   
As Reported (1)
    
Pro Forma Adjustments (2)
    
Pro Forma
    
As Reported (1)
    
Pro Forma Adjustments (2)
    
Pro Forma
  
   
Aug 31, 2023
    
Aug 31, 2023
    
Aug 31, 2023
    
Aug 31, 2022
    
Aug 31, 2022
    
Aug 31, 2022
  
         
(unaudited)
                
(unaudited)
        
                                     
Net sales
  
$
78,679
    
$
(11,935
)
  
$
66,744
    
$
81,537
    
$
(19,828
)
  
$
61,709
  
Cost of sales (exclusive of intangible amortization)
    
38,619
      
(8,482
)
    
30,137
      
39,232
      
(11,585
)
    
27,647
  
Gross profit
    
40,060
      
(3,453
)
    
36,607
      
42,305
      
(8,243
)
    
34,062
  
% of net sales
    
50.9
%
            
54.8
%
    
51.9
%
            
55.2
%
                                                 
Operating expenses
                                                
Research and development
    
7,941
      
(207
)
    
7,734
      
8,333
      
(125
)
    
8,208
  
Sales and marketing
    
27,368
      
(1,487
)
    
25,881
      
26,543
      
(1,416
)
    
25,127
  
General and administrative
    
10,856
      
(1
)
    
10,855
      
10,101
      
(101
)
    
10,000
  
Amortization of intangibles
    
3,625
      
(964
)
    
2,661
      
4,837
      
(1,448
)
    
3,389
  
Change in fair value of contingent consideration
    
(130
)
    
—
      
(130
)
    
211
      
—
      
211
  
Acquisition, restructuring and other items, net
    
3,212
      
(22
)
    
3,190
      
5,581
      
(17
)
    
5,564
  
Total operating expenses
    
52,872
      
(2,681
)
    
50,191
      
55,606
      
(3,107
)
    
52,499
  
Gain on sale of assets
    
47,842
      
(47,842
)
    
—
      
—
      
—
      
—
  
Operating income (loss)
    
35,030
      
(48,614
)
    
(13,584
)
    
(13,301
)
    
(5,136
)
    
(18,437
)
Interest expense, net
    
119
      
—
      
119
      
(381
)
    
—
      
(381
)
Other expense, net
    
(288
)
    
—
      
(288
)
    
(175
)
    
—
      
(175
)
Total other expense, net
    
(169
)
    
—
      
(169
)
    
(556
)
    
—
      
(556
)
Income (loss) before income tax benefit
    
34,861
      
(48,614
)
    
(13,753
)
    
(13,857
)
    
(5,136
)
    
(18,993
)
Income tax benefit
    
(11,023
)
    
—
      
(11,023
)
    
(853
)
            
(853
)
Net income (loss)
  
$
45,884
    
$
(48,614
)
  
$
(2,730
)
  
$
(13,004
)
  
$
(5,136
)
  
$
(18,140
)
                                                 
Income (loss) per share
                                                
Basic
  
$
1.15
            
$
(0.07
)
  
$
(0.33
)
          
$
(0.46
)
Diluted
  
$
1.15
            
$
(0.07
)
  
$
(0.33
)
          
$
(0.46
)
                                                 
Weighted average shares outstanding
                                                
Basic
    
39,842
              
39,842
      
39,302
              
39,302
  
Diluted
    
39,968
              
39,842
      
39,302
              
39,302
  
 
(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended August 31, 2023 and August 31, 2022.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
 
1
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
 
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted Net Loss:
  
   
Pro Forma
  
   
Three Months Ended
  
   
Aug 31, 2023
    
Aug 31, 2022
  
   
(unaudited)
    
(unaudited)
  
             
Pro forma net loss
  
$
(2,730
)
  
$
(18,140
)
                 
Amortization of intangibles
    
2,661
      
3,389
  
Change in fair value of contingent consideration
    
(130
)
    
211
  
Acquisition, restructuring and other items, net (1)
    
3,190
      
5,564
  
Tax effect of non-GAAP items (2)
    
(9,176
)
    
1,408
  
Adjusted pro forma net loss
  
$
(6,185
)
  
$
(7,568
)

Reconciliation of Pro Forma Diluted Loss Per Share to Pro Forma Adjusted Diluted Loss Per Share:
  
   
Pro Forma
  
   
Three Months Ended
  
   
Aug 31, 2023
    
Aug 31, 2022
  
   
(unaudited)
    
(unaudited)
  
             
Pro forma diluted loss per share
  
$
(0.07
)
  
$
(0.46
)
                 
Amortization of intangibles
    
0.07
      
0.09
  
Change in fair value of contingent consideration
    
—
      
0.01
  
Acquisition, restructuring and other items, net (1)
    
0.08
      
0.14
  
Tax effect of non-GAAP items (2)
    
(0.24
)
    
0.03
  
Adjusted pro forma diluted loss per share
  
$
(0.16
)
  
$
(0.19
)
                 
Adjusted diluted sharecount (3)
    
39,842
      
39,302
  

(1)  Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.
 
(2)  Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended August 31, 2023 and August 31, 2022.
 
(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
 
2
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands, except per share data)
 
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted EBITDA:
        
   
Pro Forma
  
   
Three Months Ended
  
   
Aug 31, 2023
    
Aug 31, 2022
  
   
(unaudited)
    
(unaudited)
  
             
Pro forma net loss
  
$
(2,730
)
  
$
(18,140
)
                 
Income tax benefit
    
(11,023
)
    
(853
)
Interest expense, net
    
(119
)
    
381
  
Depreciation and amortization
    
5,682
      
6,124
  
Change in fair value of contingent consideration
    
(130
)
    
211
  
Stock based compensation
    
4,058
      
2,937
  
Acquisition, restructuring and other items, net (1)
    
3,190
      
5,564
  
Pro forma adjusted EBITDA
  
$
(1,072
)
  
$
(3,776
)
                 
Per diluted share:
                
Adjusted EBITDA
  
$
(0.03
)
  
$
(0.10
)
 
(1)  Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.
 
3
ANGIODYNAMICS, INC. AND SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
(in thousands)
 
   
Three Months Ended
    
Three Months Ended
                                      
   
Actual (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
As
Reported (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
Actual
    
Pro Forma
  
   
Aug 31, 2023
    
Aug 31, 2023
    
Aug 31, 2023
    
Aug 31, 2022
    
Aug 31, 2022
    
Aug 31, 2022
    
% Growth
    
Currency Impact
    
Constant Currency Growth
    
%
Growth
    
Currency Impact
    
Constant Currency Growth
  
         
(unaudited)
                
(unaudited)
                                            
Net Sales
                                                                        
Med Tech
  
$
25,860
    
$
(131
)
  
$
25,729
    
$
22,817
    
$
(76
)
  
$
22,741
      
13.3
%
                
13.1
%
            
Med Device
    
52,819
      
(11,804
)
    
41,015
      
58,720
      
(19,752
)
    
38,968
      
(10.0
)%
                
5.3
%
            
   
$
78,679
    
$
(11,935
)
  
$
66,744
    
$
81,537
    
$
(19,828
)
  
$
61,709
      
(3.5
)%
    
0.0
%
    
(3.5
)%
    
8.2
%
    
0.0
%
    
8.2
%
                                                                                                 
Net Sales
                                                                                                
United States
  
$
64,399
    
$
(8,395
)
  
$
56,004
    
$
69,023
    
$
(15,150
)
  
$
53,873
      
(6.7
)%
                    
4.0
%
                
International
    
14,280
      
(3,540
)
    
10,740
      
12,514
      
(4,678
)
    
7,836
      
14.1
%
    
0.0
%
    
14.1
%
    
37.1
%
                
   
$
78,679
    
$
(11,935
)
  
$
66,744
    
$
81,537
    
$
(19,828
)
  
$
61,709
      
(3.5
)%
    
0.0
%
    
(3.5
)%
    
8.2
%
    
0.0
%
    
8.2
%

(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended August 31, 2023 and August 31, 2022.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
 
GROSS PROFIT BY PRODUCT CATEGORY
(in thousands)

   
Three Months Ended
    
Three Months Ended
              
   
Actual (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
As Reported (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
Actual
    
Pro Forma
  
   
Aug 31, 2023
    
Aug 31, 2023
    
Aug 31, 2023
    
Aug 31, 2022
    
Aug 31, 2022
    
Aug 31, 2022
    
% Change
    
% Change
  
   
(unaudited)
    
(unaudited)
              
Med Tech
  
$
16,727
    
$
(39
)
  
$
16,688
    
$
14,429
    
$
(20
)
  
$
14,409
      
15.9
%
    
15.8
%
Gross profit % of sales
    
64.7
%
            
64.9
%
    
63.2
%
            
63.4
%
                
                                                                 
Med Device
  
$
23,333
    
$
(3,414
)
  
$
19,919
    
$
27,876
    
$
(8,223
)
  
$
19,653
      
(16.3
)%
    
1.4
%
Gross profit % of sales
    
44.2
%
            
48.6
%
    
47.5
%
            
50.4
%
                
                                                                 
Total
  
$
40,060
    
$
(3,453
)
  
$
36,607
    
$
42,305
    
$
(8,243
)
  
$
34,062
      
(5.3
)%
    
7.5
%
Gross profit % of sales
    
50.9
%
            
54.8
%
    
51.9
%
            
55.2
%
                

(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended August 31 2023 and August 31, 2022.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
 
4
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share data)
 
   
Three Months Ended
    
Three Months Ended
  
   
As Reported (1)
    
Pro Forma Adjustments (2)
    
Pro Forma
    
As Reported (1)
    
Pro Forma Adjustments (2)
    
Pro Forma
  
   
Nov 30, 2023
    
Nov 30, 2023
    
Nov 30, 2023
    
Nov 30, 2022
    
Nov 30, 2022
    
Nov 30, 2022
  
         
(unaudited)
                
(unaudited)
        
                                     
Net sales
  
$
79,073
    
$
(12,190
)
  
$
66,883
    
$
85,429
    
$
(20,810
)
  
$
64,619
  
Cost of sales (exclusive of intangible amortization)
    
38,811
      
(8,600
)
    
30,211
      
40,351
      
(12,023
)
    
28,328
  
Gross profit
    
40,262
      
(3,590
)
    
36,672
      
45,078
      
(8,787
)
    
36,291
  
% of net sales
    
50.9
%
            
54.8
%
    
52.8
%
            
56.2
%
                                                 
Operating expenses
                                                
Research and development
    
8,658
      
(323
)
    
8,335
      
6,838
      
(127
)
    
6,711
  
Sales and marketing
    
25,464
      
(1,469
)
    
23,995
      
26,007
      
(1,485
)
    
24,522
  
General and administrative
    
9,289
      
(74
)
    
9,215
      
10,835
      
(831
)
    
10,004
  
Amortization of intangibles
    
3,562
      
(964
)
    
2,598
      
4,808
      
(1,448
)
    
3,360
  
Change in fair value of contingent consideration
    
221
      
—
      
221
      
1,646
      
—
      
1,646
  
Acquisition, restructuring and other items, net
    
6,188
      
(106
)
    
6,082
      
3,059
      
—
      
3,059
  
Total operating expenses
    
53,382
      
(2,936
)
    
50,446
      
53,193
      
(3,891
)
    
49,302
  
Operating loss
    
(13,120
)
    
(654
)
    
(13,774
)
    
(8,115
)
    
(4,896
)
    
(13,011
)
Interest expense, net
    
534
      
—
      
534
      
(684
)
    
—
      
(684
)
Other expense, net
    
(32
)
    
—
      
(32
)
    
(252
)
    
—
      
(252
)
Total other expense, net
    
502
      
—
      
502
      
(936
)
    
—
      
(936
)
Loss before income tax benefit
    
(12,618
)
    
(654
)
    
(13,272
)
    
(9,051
)
    
(4,896
)
    
(13,947
)
Income tax (benefit) expense
    
16,430
      
—
      
16,430
      
(565
)
            
(565
)
Net loss
  
$
(29,048
)
  
$
(654
)
  
$
(29,702
)
  
$
(8,486
)
  
$
(4,896
)
  
$
(13,382
)
                                                 
Loss per share
                                                
Basic
  
$
(0.72
)
          
$
(0.74
)
  
$
(0.21
)
          
$
(0.34
)
Diluted
  
$
(0.72
)
          
$
(0.74
)
  
$
(0.21
)
          
$
(0.34
)
                                                 
Weighted average shares outstanding
                                                
Basic
    
40,219
              
40,219
      
39,490
              
39,490
  
Diluted
    
40,219
              
40,219
      
39,490
              
39,490
  
 
(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended November 30, 2023 and November 30, 2022.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
 
5
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
 
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted Net Loss:
  
   
Pro Forma
  
   
Three Months Ended
  
   
Nov 30, 2023
    
Nov 30, 2022
  
   
(unaudited)
    
(unaudited)
  
             
Pro forma net loss
  
$
(29,702
)
  
$
(13,382
)
                 
Amortization of intangibles
    
2,598
      
3,360
  
Change in fair value of contingent consideration
    
221
      
1,646
  
Acquisition, restructuring and other items, net (1)
    
6,082
      
3,059
  
Tax effect of non-GAAP items (2)
    
17,435
      
788
  
Adjusted pro forma net loss
  
$
(3,366
)
  
$
(4,529
)

Reconciliation of Pro Forma Diluted Loss Per Share to Pro Forma Adjusted Diluted Loss Per Share:
  
   
Pro Forma
  
   
Three Months Ended
  
   
Nov 30, 2023
    
Nov 30, 2022
  
   
(unaudited)
    
(unaudited)
  
             
Pro forma diluted loss per share
  
$
(0.74
)
  
$
(0.34
)
                 
Amortization of intangibles
    
0.06
      
0.09
  
Change in fair value of contingent consideration
    
0.01
      
0.04
  
Acquisition, restructuring and other items, net (1)
    
0.15
      
0.08
  
Tax effect of non-GAAP items (2)
    
0.44
      
0.02
  
Adjusted pro forma diluted loss per share
  
$
(0.08
)
  
$
(0.11
)
                 
Adjusted diluted sharecount (3)
    
40,219
      
39,490
  

(1)  Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.
 
(2)  Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended November 30, 2023 and November 30, 2022.
 
(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
 
6
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands, except per share data)
 
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted EBITDA:
        
   
Pro Forma
  
   
Three Months Ended
  
   
Nov 30, 2023
    
Nov 30, 2022
  
   
(unaudited)
    
(unaudited)
  
             
Pro forma net loss
  
$
(29,702
)
  
$
(13,382
)
                 
Income tax benefit
    
16,430
      
(565
)
Interest expense, net
    
(534
)
    
684
  
Depreciation and amortization
    
5,691
      
6,268
  
Change in fair value of contingent consideration
    
221
      
1,646
  
Stock based compensation
    
1,802
      
3,287
  
Acquisition, restructuring and other items, net (1)
    
6,082
      
3,059
  
Pro forma adjusted EBITDA
  
$
(10
)
  
$
997
  
                 
Per diluted share:
                
Adjusted EBITDA
  
$
—
    
$
0.02
  
 
(1)  Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.
 
7
ANGIODYNAMICS, INC. AND SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
(in thousands)
 
   
Three Months Ended
    
Three Months Ended
                                      
   
Actual (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
As
Reported (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
Actual
    
Pro Forma
  
   
Nov 30, 2023
    
Nov 30, 2023
    
Nov 30, 2023
    
Nov 30, 2022
    
Nov 30, 2022
    
Nov 30, 2022
    
% Growth
    
Currency Impact
    
Constant Currency Growth
    
%
Growth
    
Currency Impact
    
Constant Currency Growth
  
         
(unaudited)
                
(unaudited)
                                            
Net Sales
                                                                        
Med Tech
  
$
25,363
    
$
(122
)
  
$
25,241
    
$
24,502
    
$
(135
)
  
$
24,367
      
3.5
%
                
3.6
%
            
Med Device
    
53,710
      
(12,068
)
    
41,642
      
60,927
      
(20,675
)
    
40,252
      
(11.8
)%
                
3.5
%
            
   
$
79,073
    
$
(12,190
)
  
$
66,883
    
$
85,429
    
$
(20,810
)
  
$
64,619
      
(7.4
)%
    
0.0
%
    
(7.4
)%
    
3.5
%
    
0.0
%
    
3.5
%
                                                                                                 
Net Sales
                                                                                                
United States
  
$
64,002
    
$
(8,182
)
  
$
55,820
    
$
71,631
    
$
(16,413
)
  
$
55,218
      
(10.7
)%
                    
1.1
%
                
International
    
15,071
      
(4,008
)
    
11,063
      
13,798
      
(4,397
)
    
9,401
      
9.2
%
    
0.0
%
    
9.2
%
    
17.7
%
                
   
$
79,073
    
$
(12,190
)
  
$
66,883
    
$
85,429
    
$
(20,810
)
  
$
64,619
      
(7.4
)%
    
0.0
%
    
(7.4
)%
    
3.5
%
    
0.0
%
    
3.5
%

(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended November 30, 2023 and November 30, 2022.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

GROSS PROFIT BY PRODUCT CATEGORY
(in thousands)
   
Three Months Ended
    
Three Months Ended
              
   
Actual (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
As Reported (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
Actual
    
Pro Forma
  
   
Nov 30, 2023
    
Nov 30, 2023
    
Nov 30, 2023
    
Nov 30, 2022
    
Nov 30, 2022
    
Nov 30, 2022
    
% Change
    
% Change
  
   
(unaudited)
    
(unaudited)
              
Med Tech
  
$
15,816
    
$
(33
)
  
$
15,783
    
$
15,614
    
$
(50
)
  
$
15,564
      
1.3
%
    
1.4
%
Gross profit % of sales
    
62.4
%
            
62.5
%
    
63.7
%
            
63.9
%
                
                                                                 
Med Device
  
$
24,446
    
$
(3,557
)
  
$
20,889
    
$
29,464
    
$
(8,737
)
  
$
20,727
      
(17.0
)%
    
0.8
%
Gross profit % of sales
    
45.5
%
            
50.2
%
    
48.4
%
            
51.5
%
                
                                                                 
Total
  
$
40,262
    
$
(3,590
)
  
$
36,672
    
$
45,078
    
$
(8,787
)
  
$
36,291
      
(10.7
)%
    
1.0
%
Gross profit % of sales
    
50.9
%
            
54.8
%
    
52.8
%
            
56.2
%
                

(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended November 30, 2023 and November 30, 2022.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
 
8
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share data)
 
   
Three Months Ended
    
Three Months Ended
  
   
As Reported (1)
    
Pro Forma Adjustments (2)
    
Pro Forma
    
As Reported (1)
    
Pro Forma Adjustments (2)
    
Pro Forma
  
   
Feb 29, 2024
    
Feb 29, 2024
    
Feb 29, 2024
    
Feb 28, 2023
    
Feb 28, 2023
    
Feb 28, 2023
  
         
(unaudited)
                
(unaudited)
        
                                     
Net sales
  
$
75,182
    
$
(9,211
)
  
$
65,971
    
$
80,712
    
$
(19,622
)
  
$
61,090
  
Cost of sales (exclusive of intangible amortization)
    
39,321
      
(7,038
)
    
32,283
      
40,208
      
(12,096
)
    
28,112
  
Gross profit
    
35,861
      
(2,173
)
    
33,688
      
40,504
      
(7,526
)
    
32,978
  
% of net sales
    
47.7
%
            
51.1
%
    
50.2
%
            
54.0
%
                                                 
Operating expenses
                                                
Research and development
    
8,189
      
(117
)
    
8,072
      
6,852
      
(139
)
    
6,713
  
Sales and marketing
    
25,405
      
(1,758
)
    
23,647
      
25,406
      
(1,404
)
    
24,002
  
General and administrative
    
10,578
      
22
      
10,600
      
8,839
      
(306
)
    
8,533
  
Amortization of intangibles
    
3,287
      
(643
)
    
2,644
      
4,739
      
(1,448
)
    
3,291
  
Goodwill impairment
    
159,476
      
—
      
159,476
      
—
      
—
      
—
  
Change in fair value of contingent consideration
    
112
      
—
      
112
      
227
      
—
      
227
  
Acquisition, restructuring and other items, net
    
35,367
      
(6,266
)
    
29,101
      
3,369
      
—
      
3,369
  
Total operating expenses
    
242,414
      
(8,762
)
    
233,652
      
49,432
      
(3,297
)
    
46,135
  
Gain on sale of assets
    
6,657
      
(6,657
)
    
—
      
—
      
—
      
—
  
Operating loss
    
(199,896
)
    
(68
)
    
(199,964
)
    
(8,928
)
    
(4,229
)
    
(13,157
)
Interest expense, net
    
394
      
—
      
394
      
(736
)
    
—
      
(736
)
Other expense, net
    
(238
)
    
—
      
(238
)
    
—
      
—
      
—
  
Total other expense, net
    
156
      
—
      
156
      
(736
)
    
—
      
(736
)
Loss before income tax benefit
    
(199,740
)
    
(68
)
    
(199,808
)
    
(9,664
)
    
(4,229
)
    
(13,893
)
Income tax benefit
    
(12,004
)
    
—
      
(12,004
)
    
(179
)
            
(179
)
Net loss
  
$
(187,736
)
  
$
(68
)
  
$
(187,804
)
  
$
(9,485
)
  
$
(4,229
)
  
$
(13,714
)
                                                 
Loss per share
                                                
Basic
  
$
(4.67
)
          
$
(4.67
)
  
$
(0.24
)
          
$
(0.35
)
Diluted
  
$
(4.67
)
          
$
(4.67
)
  
$
(0.24
)
          
$
(0.35
)
                                                 
Weighted average shares outstanding
                                                
Basic
    
40,234
              
40,234
      
39,509
              
39,509
  
Diluted
    
40,234
              
40,234
      
39,509
              
39,509
  
 
(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 29, 2024 and February 28, 2023.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
 
9
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
 
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted Net Loss:
  
   
Pro Forma
  
   
Three Months Ended
  
   
Feb 29, 2024
    
Feb 28, 2023
  
   
(unaudited)
    
(unaudited)
  
             
Pro forma net loss
  
$
(187,804
)
  
$
(13,714
)
                 
Amortization of intangibles
    
2,644
      
3,291
  
Change in fair value of contingent consideration
    
112
      
227
  
Acquisition, restructuring and other items, net (1)
    
29,101
      
3,369
  
Goodwill impairment
    
159,476
      
—
  
Tax effect of non-GAAP items (2)
    
(10,055
)
    
1,432
  
Adjusted pro forma net loss
  
$
(6,526
)
  
$
(5,395
)

Reconciliation of Pro Forma Diluted Loss Per Share to Pro Forma Adjusted Diluted Loss Per Share:
  
   
Pro Forma
  
   
Three Months Ended
  
   
Feb 29, 2024
    
Feb 28, 2023
  
   
(unaudited)
    
(unaudited)
  
                 
Pro forma diluted loss per share
  
$
(4.67
)
  
$
(0.35
)
                 
Amortization of intangibles
    
0.07
      
0.08
  
Change in fair value of contingent consideration
    
—
      
0.01
  
Acquisition, restructuring and other items, net (1)
    
0.72
      
0.08
  
Goodwill impairment
    
3.97
      
—
  
Tax effect of non-GAAP items (2)
    
(0.25
)
    
0.04
  
Adjusted pro forma diluted loss per share
  
$
(0.16
)
  
$
(0.14
)
                 
Adjusted diluted sharecount (3)
    
40,234
      
39,509
  

(1)  Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.
 
(2)  Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended February 29, 2024 and February 28, 2023.
 
(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
 
10
ANGIODYNAMICS, INC. AND SUBSIDIARIES
PRO FORMA GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands, except per share data)
 
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted EBITDA:
        
   
Pro Forma
  
   
Three Months Ended
  
   
Feb 29, 2024
    
Feb 28, 2023
  
   
(unaudited)
    
(unaudited)
  
             
Pro forma net loss
  
$
(187,804
)
  
$
(13,714
)
                 
Income tax benefit
    
(12,004
)
    
(179
)
Interest expense, net
    
(394
)
    
736
  
Depreciation and amortization
    
6,861
      
6,288
  
Goodwill impairment
    
159,476
      
—
  
Change in fair value of contingent consideration
    
112
      
227
  
Stock based compensation
    
2,141
      
1,728
  
Acquisition, restructuring and other items, net (1)
    
27,966
      
3,369
  
Pro forma adjusted EBITDA
  
$
(3,646
)
  
$
(1,545
)
                 
Per diluted share:
                
Adjusted EBITDA
  
$
(0.09
)
  
$
(0.04
)
 
(1)  Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.
 
11
ANGIODYNAMICS, INC. AND SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
 (in thousands)
 
   
Three Months Ended
    
Three Months Ended
                                      
   
Actual (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
As
Reported (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
Actual
    
Pro Forma
  
   
Feb 29, 2024
    
Feb 29, 2024
    
Feb 29, 2024
    
Feb 28,
2023
    
Feb 28, 2023
    
Feb 28, 2023
    
% Growth
    
Currency Impact
    
Constant Currency Growth
    
%
Growth
    
Currency Impact
    
Constant Currency Growth
  
         
(unaudited)
                
(unaudited)
                                            
Net Sales
                                                                        
Med Tech
  
$
25,844
    
$
(190
)
  
$
25,654
    
$
22,874
    
$
(91
)
  
$
22,783
      
13.0
%
                
12.6
%
            
Med Device
    
49,338
      
(9,021
)
    
40,317
      
57,838
      
(19,531
)
    
38,307
      
(14.7
)%
                
5.2
%
            
   
$
75,182
    
$
(9,211
)
  
$
65,971
    
$
80,712
    
$
(19,622
)
  
$
61,090
      
(6.9
)%
    
0.0
%
    
(6.9
)%
    
8.0
%
    
0.0
%
    
8.0
%
                                                                                                 
Net Sales
                                                                                                
United States
  
$
62,342
    
$
(6,521
)
  
$
55,821
    
$
67,620
    
$
(14,932
)
  
$
52,688
      
(7.8
)%
                    
5.9
%
                
International
    
12,840
      
(2,690
)
    
10,150
      
13,092
      
(4,690
)
    
8,402
      
(1.9
)%
    
0.0
%
    
(1.9
)%
    
20.8
%
                
   
$
75,182
    
$
(9,211
)
  
$
65,971
    
$
80,712
    
$
(19,622
)
  
$
61,090
      
(6.9
)%
    
0.0
%
    
(6.9
)%
    
8.0
%
    
0.0
%
    
8.0
%

(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 29, 2024 and February 28, 2023.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
 
GROSS PROFIT BY PRODUCT CATEGORY
(in thousands)

   
Three Months Ended
    
Three Months Ended
              
   
Actual (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
As Reported (1)
    
Pro Forma
Adj. (2)
    
Pro Forma
    
Actual
    
Pro Forma
  
   
Feb 29, 2024
    
Feb 29, 2024
    
Feb 29, 2024
    
Feb 28, 2023
    
Feb 28, 2023
    
Feb 28, 2023
    
% Change
    
% Change
  
   
(unaudited)
    
(unaudited)
              
Med Tech
  
$
15,857
    
$
(83
)
  
$
15,774
    
$
14,774
    
$
(93
)
  
$
14,681
      
7.3
%
    
7.4
%
Gross profit % of sales
    
61.4
%
            
61.5
%
    
64.6
%
            
64.4
%
                
                                                                 
Med Device
  
$
20,004
    
$
(2,090
)
  
$
17,914
    
$
25,730
    
$
(7,433
)
  
$
18,297
      
(22.3
)%
    
(2.1
)%
Gross profit % of sales
    
40.5
%
            
44.4
%
    
44.5
%
            
47.8
%
                
                                                                 
Total
  
$
35,861
    
$
(2,173
)
  
$
33,688
    
$
40,504
    
$
(7,526
)
  
$
32,978
      
(11.5
)%
    
2.2
%
Gross profit % of sales
    
47.7
%
            
51.1
%
    
50.2
%
            
54.0
%
                

(1)  Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 29, 2024 and February 28, 2023.
 
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
 

12